Abstract

Background/PurposeSurgery followed by postoperative radiotherapy (RT) has been considered the standard treatment for oral cavity squamous cell carcinoma (OCSCC) of advanced stages or with adverse prognostic factors. In this study, we compared the outcomes in patients with OCSCC who received postoperative concurrent chemoradiotherapy (CCRT) or postoperative RT alone using modern RT techniques.MethodsA total of 275 patients with OCSCC treated between 2002 and 2018 were retrospectively analyzed. Adverse prognostic factor was defined as extranodal extension (ENE), microscopically involved surgical margin, involvement of ≥2 lymph nodes, perineural disease, and/or lymphovascular invasion (LVI). In total, 148 patients (54%) received CCRT and 127 patients (46%) received RT alone. More patients in the CCRT group had N3 disease and stage IVB disease (46.6% vs. 10.2%, p<0.001), ENE (56.1% vs. 15.7%, p<0.001), LVI (28.4% vs. 13.4%, p=0.033).ResultsWith a median follow-up of 40 (range, 5–203) months, there were no significant differences in the 5-year overall survival (OS) and PFS between treatment groups. In the subgroup analysis according to high risk, the concurrent use of chemotherapy showed significantly improved OS in patients with ENE (HR 0.39, p=0.003).ConclusionOur retrospective study showed that postoperative CCRT group had comparable survival outcomes to those in the RT alone group for advanced OCSCC in the era of modern RT techniques and indicated that concurrent chemotherapy should be administered to patients with ENE. Prospective randomized studies for confirmation are needed.

Highlights

  • Squamous cell carcinoma (SCC) is the most common malignancy of the oral cavity [1]

  • A total of 119 patients (43%) had stage IVA disease according to American Joint Committee On Cancer (AJCC) 8th edition and 82 patients (30%) had stage IVB disease

  • In the subgroup analysis according to high risk (ENE, RM+, perineural invasion (PNI), lymphovascular invasion (LVI), and multiple node), the concurrent use of chemotherapy showed significantly improved overall survival (OS) in patients with extranodal extension (ENE) (HR 0.39, 95% confidence interval (CI) 0.21–0.43, p = 0.003, Figure 3), while there was no advantage in OS in patients with RM+, PNI, LVI, and multiple node

Read more

Summary

Introduction

It is estimated that 35,130 people will be diagnosed with oral cavity cancer in 2019 [2]. Surgery followed by postoperative radiotherapy (PORT) is considered the standard treatment for oral cavity SCC (OCSCC) of advanced stages or with adverse prognostic factors. Patients with OCSCC tend to have worse local and regional control compared to other head and neck subsites [3,4,5]. Evidence for the concurrent use of chemotherapy was established by the European Organization for Research and Treatment of Cancer (EORTC) 22931 and Radiation Therapy Oncology Group (RTOG) 9501 trials [6, 7]. Concurrent chemotherapy with cisplatin was administrated for high risk patients and reported that 5-year overall survival (OS) was approximately 50%

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call